Association between clinical evidence and reimbursement access for approved Chinese patent medicines in China

Clinical evidence is an important consideration in drug reimbursement decisions, yet its role in the reimbursement of Chinese patent medicines (CPMs) remains poorly understood. This study examined the association between clinical trial evidence and reimbursement inclusion for CPMs. We identified 187 CPMs approved between January 2010 and June 2024, of which 125 met the eligibility criteria. Clinical trial evidence was characterized using an eight-domain evidence score and comparative clinical benefit. Associations with China’s National Reimbursement Drug List (NRDL) inclusion were estimated using Firth penalized logistic regression with adjustment for drug-level characteristics. Among 125 CPMs, 43 (34.40%) were included in the NRDL. In the fully adjusted model, each 1-point increase in the clinical trial evidence score was associated with greater odds of NRDL inclusion (OR, 2.19; 95% CI, 1.31–3.69; p = 0.003). Compared with CPMs for which clinical benefit was not reported, higher odds of inclusion were observed for those with a clinical benefit rate < 50% (OR, 13.51; 95% CI, 1.86–97.98; p = 0.010) and ≥ 50% (OR, 19.45; 95% CI, 1.79–211.07; p = 0.015). A higher clinical trial evidence score and the availability of estimable comparative clinical benefit were associated with greater odds of NRDL inclusion. Strengthening the design, conduct, and reporting of CPM clinical trials may support more evidence-informed reimbursement decisions and the continued standardization of CPM clinical research.

Authors

Institutions

Publication Details

Journal
BMC Complementary Medicine and Therapies
Published
2026-11-18
DOI
https://doi.org/10.1186/s12906-026-05671-1
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association between clinical evidence and reimbursement access for approved Chinese patent medicines in China

Lian Yang, Jia Li, Haijing Guan, Yi Guo
1 links
BMC Complementary Medicine and Therapies
Pharmaceutical Economics and Policy
article

Association between clinical evidence and reimbursement access for approved Chinese patent medicines in China

Lian Yang, Jia Li, Haijing Guan, Yi Guo
article en

Abstract

Clinical evidence is an important consideration in drug reimbursement decisions, yet its role in the reimbursement of Chinese patent medicines (CPMs) remains poorly understood. This study examined the association between clinical trial evidence and reimbursement inclusion for CPMs. We identified 187 CPMs approved between January 2010 and June 2024, of which 125 met the eligibility criteria. Clinical trial evidence was characterized using an eight-domain evidence score and comparative clinical benefit. Associations with China’s National Reimbursement Drug List (NRDL) inclusion were estimated using Firth penalized logistic regression with adjustment for drug-level characteristics. Among 125 CPMs, 43 (34.40%) were included in the NRDL. In the fully adjusted model, each 1-point increase in the clinical trial evidence score was associated with greater odds of NRDL inclusion (OR, 2.19; 95% CI, 1.31–3.69; p = 0.003). Compared with CPMs for which clinical benefit was not reported, higher odds of inclusion were observed for those with a clinical benefit rate < 50% (OR, 13.51; 95% CI, 1.86–97.98; p = 0.010) and ≥ 50% (OR, 19.45; 95% CI, 1.79–211.07; p = 0.015). A higher clinical trial evidence score and the availability of estimable comparative clinical benefit were associated with greater odds of NRDL inclusion. Strengthening the design, conduct, and reporting of CPM clinical trials may support more evidence-informed reimbursement decisions and the continued standardization of CPM clinical research.

BMC Complementary Medicine and Therapies
Capital Medical University (CN), Peking University (CN), Beijing Tian Tan Hospital (CN), Chengdu University of Traditional Chinese Medicine (CN)
Good health and well-being
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon